-Reuters
Starton Therapeutics Receives Authorization From The FDA To Proceed With STAR-LLD Lenalidomide Phase 1b Clinical Trial In Multiple Myeloma
FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myelomaTreatment regimen will include Velcade® (bortezomib) and dexamethasone and replace oral Revlimid® with